Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2024-02-27 00:00:00 ET · period of report 2024-02-23 · accession 0001415889-24-005572 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-27 | 2024-02-23 | ACAD | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +10.9K | 107.5K | +11% | — |
| D | 2024-02-27 | 2024-02-26 | ACAD | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $24.67 | -5,577 | 101.9K | -5% | -$137.6K |
| D | 2024-02-27 | 2024-02-23 | ACAD | DAVIS STEPHEN | CEO, Dir | M - OptEx | $0.00 | -10.9K | 10.9K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-23 | M | A | 10,946 | — | 107,467 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| 2 | Common | Common Stock | 2024-02-26 | S | D | 5,577 | $24.67 | 101,890 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2024-02-23 | M | D | 10,946 | $0.00 | 10,946 | D | — · — to — | 10,946 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F3) The restricted stock units vest in four equal annual installments beginning February 23, 2022. |